<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03822897</url>
  </required_header>
  <id_info>
    <org_study_id>HN10</org_study_id>
    <nct_id>NCT03822897</nct_id>
  </id_info>
  <brief_title>De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma</brief_title>
  <acronym>EVADER</acronym>
  <official_title>A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether radiotherapy to some of the lymph node areas
      can be safely omitted to decrease side effects without increasing the risk of the tumour
      coming back.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard or usual treatment for this disease includes radiotherapy or radiotherapy
      combined with chemotherapy or antibody therapy.

      These treatments are highly effective at curing most patients with HPV-related cancer of the
      oropharynx, but short and long-term side effects from treatment can be significant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time to first progress event or censoring in year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time to death or censoring in year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of patients with local control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional Control</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of patients with regional control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional control</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of patients with local and regional control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Metastasis-Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time to distant metastasis or censoring in year</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Oropharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Two Treatment Options</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Option #1 - Radiotherapy 35 fractions, 5/wk, 7 wks 70Gy/56Gy Cisplatin 100mg/m2 on day 1, 22 and 43 or 40mg mg/m2/wk for 7 wks
Option #2 - Radiation only-35 fraction, 6/wk, 6wks 70Gy/56Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>35 fractions, 5/wk, 7 wks 70Gy/56Gy, or
35 fractions, 6/wk, 6 wks, 70Gy/56Gy, or
35 fractions, 5/wk, 7 wks OR 6/wk, 6 wks 70Gy/56Gy</description>
    <arm_group_label>Two Treatment Options</arm_group_label>
    <other_name>No available</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>100 mg/m2 on day 1, 22, and 43 or 40 mg/m2 /wk for 7 wks</description>
    <arm_group_label>Two Treatment Options</arm_group_label>
    <other_name>No available</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pathologically proven diagnosis of HPV-related OPSCC

          -  Clinical stage T1-3 N0-1 M0 (UICC/AJCC 8th Ed.)

          -  Patients must be eligible for definitive RT or CRT

          -  Must be â‰¥ 18 years of age

          -  Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or
             2

          -  Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life
             and health economics questionnaires in either English or French

          -  Patient consent must be appropriately obtained in accordance with applicable local and
             regulatory requirements. Each patient must sign a consent form prior to enrolment in
             the trial to document their willingness to participate

          -  Patients must be accessible for treatment and follow up. Patients registered on this
             trial must be treated and followed at the participating centre

          -  In accordance with CCTG policy, protocol treatment is to begin within 3 weeks of
             patient registration

          -  Women/men of childbearing potential must have agreed to use a highly effective
             contraceptive method

          -  The following radiological investigations must be done within 8 weeks of
             randomization: CT or MR of head and neck (MRI is recommended for base-of-tongue
             primary tumors); PET-CT scan.

          -  Patient must consent to provision of and investigator must confirm adequacy of
             non-cytology tissue samples and confirm access to and agree to submit within 4 weeks
             of randomization to the CCTG Central Tumour Bank, a representative formalin fix
             paraffin block of non-cytology tumour tissue in order that the specific correlative
             marker assays described may be conducted.

          -  Patient must consent to provision of samples of blood and plasma (for circulating cell
             free DNA) in order that the specific correlative marker assays described may be
             conducted.

          -  Patients with prior or concurrent malignancy whose natural history or treatment does
             not have the potential to interfere with the safety or efficacy assessment of the
             investigational regimen are eligible for this trial.

        Exclusion Criteria:

          -  Previous chemotherapy or radiotherapy treatment for head and neck cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Bratman</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Cancer Centre, Toronto, ON</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendy Parulekar</last_name>
    <phone>613-533-6430</phone>
    <email>wparulekar@ctg.queensu.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>BCCA - Centre for the North</name>
      <address>
        <city>Prince George</city>
        <state>British Columbia</state>
        <zip>V2M 7E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Olson</last_name>
      <phone>250 645-7300</phone>
      <phone_ext>687489</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Butler</last_name>
      <phone>204 787-2153</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. H. Bliss Murphy Cancer Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Pochini</last_name>
      <phone>709 777-7805</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khaled O. Zaza</last_name>
      <phone>613 544-2631</phone>
      <phone_ext>4173</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Gaudet</last_name>
      <phone>613 737-7700</phone>
      <phone_ext>70206</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Karam</last_name>
      <phone>416 480-4974</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Bratman</last_name>
      <phone>416 946-4501</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khalil Sultanem</last_name>
      <phone>514 340-8288</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Research Institute of the McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Shenouda</last_name>
      <phone>514 934-8040</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hotel-Dieu de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Fortin</last_name>
      <phone>418 691-5264</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Estrie - Centre hospitalier</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle C. Gauthier</last_name>
      <phone>819 346-1110</phone>
      <phone_ext>14610</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Giambattista</last_name>
      <phone>306 766-2296</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 18, 2019</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

